Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
12
×
Tags
boston blog main
life sciences
national blog main
rna interference
12
×
boston top stories
clinical trials
alnylam pharmaceuticals
national top stories
fda
new york blog main
boston
new york top stories
san francisco blog main
biotech
deals
san francisco top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
amgen
drugs
indiana blog main
indiana top stories
national
patisiran
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
gene therapy
hereditary transthyretin amyloidosis
raleigh-durham blog main
raleigh-durham top stories
sanofi
seattle blog main
seattle top stories
startups
What
drug
rna
alnylam
fda
medicines
pharmaceuticals
rnai
interference
medicine
ago
bio
gene
long
new
roundup
aren’t
cholesterol
data
deal
dicerna
gets
market
medco
ok
patients
pharma
second
seek
speedy
therapy
time
abandoning
acquire
afternoon
agreed
alliance
alnylam’s
alzheimer’s
approval
approve
Language
unset
Current search:
photo
×
" rna interference "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”